Portal hypertension secondary to myelofibrosis with myeloid metaplasia:A study of 13 cases

被引:8
|
作者
Mohannad Abu-Hilal [1 ]
Jayant Tawaker [1 ]
机构
[1] Department of Internal Medicine,Division of Gastroenterology,Mayo Clinic College of Medicine,Rochester
关键词
Portal hypertension; Myelofibrosis; Myeloid metaplasia; Ascites; Variceal bleeding;
D O I
暂无
中图分类号
R575.2 [肝硬变]; R551.3 [骨髓疾病];
学科分类号
1002 ; 100201 ;
摘要
AIM:To describe the clinical presentation and complications of portal hypertension (PH) secondary to myelofibrosis with myeloid metaplasia (MMM).METHODS: Medical records for 123 patients with MMM were reviewed.RESULTS: Thirteen patients with PH secondary to MMM were identified. Median ages at time of MMM and PH diagnosis were 61 and 66 years, respectively. The interval from MMM diagnosis to presentation with one of the PH features ranged from 1 to 11 years. Variceal bleeding and ascites were the most common presentations. Of the eight patients who presented with variceal bleeding, six patients underwent endoscopic variceal ligation (EVL) with no variceal recurrence or hematological worsening during a 12-mo follow up period.CONCLUSION: Patients with MMM might develop PH. Exact mechanisms leading to PH in MMM are still controversial. As in other etiologies, variceal bleeding and ascites are the most common presentations. Anemia may correlate with, and/or predict, the severity of the PH presentation in these patients. EVL can successfully control variceal bleeding in MMM. Further clinical studies are required.
引用
收藏
页码:3128 / 3133
页数:6
相关论文
共 50 条
  • [21] RECOMBINANT-HUMAN-ERYTHROPOIETIN THERAPY IN PATIENTS WITH MYELOFIBROSIS WITH MYELOID METAPLASIA
    TEFFERI, A
    SILVERSTEIN, MN
    BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (04) : 893 - 893
  • [22] Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia
    Pozzato, G
    Zorat, F
    Nascimben, F
    Comar, C
    Kikic, F
    Festini, G
    HAEMATOLOGICA, 2001, 86 (07) : 772 - 773
  • [23] Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis
    M.C. Le Bousse-Kerdilès
    M. C. Martyré
    Annals of Hematology, 1999, 78 : 437 - 444
  • [24] Dual implication of fibrogenic:: cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis
    Le Bousse-Kerdilès, MC
    Martyré, MC
    ANNALS OF HEMATOLOGY, 1999, 78 (10) : 437 - 444
  • [25] Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study
    Piccaluga, PP
    Visani, G
    Pileri, SA
    Ascani, S
    Grafone, T
    Isidori, A
    Malagola, M
    Finelli, C
    Martinelli, G
    Ricci, P
    Baccarani, M
    Tura, S
    LEUKEMIA, 2002, 16 (09) : 1609 - 1614
  • [26] Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study
    PP Piccaluga
    G Visani
    SA Pileri
    S Ascani
    T Grafone
    A Isidori
    M Malagola
    C Finelli
    G Martinelli
    P Ricci
    M Baccarani
    S Tura
    Leukemia, 2002, 16 : 1609 - 1614
  • [27] Portal hypertension secondary to arterioportal fistulae: two unusual cases
    Aithal, GP
    Alabdi, BJ
    Rose, JDG
    James, OFW
    Hudson, M
    LIVER, 1999, 19 (04): : 343 - 347
  • [28] Chronic Idiopathic Myelofibrosis with Myeloid Metaplasia Presenting as Refractory Ascites
    Patra, Bijoy
    Maheshwari, Anu
    Chandra, Jagdish
    Aneja, Satinder
    Agarwal, Shilpi
    Nangia, Anita
    Seth, Anju
    PEDIATRIC BLOOD & CANCER, 2010, 54 (01) : 151 - 153
  • [29] Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models
    Chagraoui, Hedia
    Wendling, Francoise
    Vainchenker, William
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (03) : 399 - 412
  • [30] Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000
    Cervantes, F
    PATHOLOGIE BIOLOGIE, 2001, 49 (02): : 148 - 152